Myocardial protective effect of tropisetron

The protective effect of tropisetron on postoperative cardiac biomarkers in patients undergoing heart valve replacement surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800018681

Enrollment

Unknown

Registered

2018-10-03

Start date

2018-08-01

Completion date

Unknown

Last updated

2018-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular disease

Interventions

Control group:Normal saline injection

Tropisetron group:Tropisetron injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients Aged 35-70 years, ASA II-III status, prepared to receive cardiac valves replacement.

Exclusion criteria

Exclusion criteria: Patients with an LVEF50 stenosis, uncontrolled hypertension, and severe brain, renal, pulmonary, hepatic disease, any serious allergy to tropisetron, any contraindication to midazolam, sufentanil, rocuronium bromide, and propofol, any administration of serotonin reuptake inhibitors in the past 3months.

Design outcomes

Primary

Measure	Time frame
Cardiac troponin I;Creatine kinase MB;Postoperative pain score;	—

Secondary

Measure	Time frame
Heart rate;Blood pressure;Central venous pressure;IL-1B;TNF-a;	—

Countries

China

Contacts

Public ContactXingrui Gong

Anesthesiology department of Taihe hospital, Shiyan, Hubei

40415311@qq.com+86 15707286813

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026